Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23190221 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
Conditions: Chronic Myelogenous Leukemia;   Hematologic Malignancies
Intervention: Drug: Ponatinib, AP24534

Indicates status has not been verified in more than two years